ASCO first-line treatment of specific non-small cell lung cancer, Novartis announces overall survival data for MET inhibitors

▎The content team editor of WuXi AppTec recently, at the American Society of Clinical Oncology (ASCO) in 2021, Novartis announced the oral high-selective small molecule MET inhibitor Tabrecta (capmatinib) for the treatment of metastatic non-small cell lung cancer (NSCLC) The latest Phase 2 clinical trial data for adult patients
.

These patients carry a genetic mutation that causes the skipping of exon 14 of the MET gene (METex14)
.

The press release pointed out that this is the first time that Novartis has released Tabrecta's overall survival data
.

Tabrecta is the first targeted therapy approved by the FDA to treat this patient group
.

The results of the test showed that the median overall survival (OS) of the newly treated patients and the treated patients were 20.
8 months and 13.
6 months, respectively
.

In addition, the total remission rates of newly-treated patients and treated patients were 67.
9% (95% CI: 47.
6, 84.
1) and 40.
6% (95% CI: 28.
9, 53.
1), respectively
.

In terms of safety, no new safety signals or unexpected safety results were observed
.

98% of subjects had at least one adverse event (AE) of any grade, most AEs were grade 3 or 4, and 50.
9% of subjects had at least one serious adverse event (SAE)
.

13% of AEs were suspected to be related to treatment
.

The most common adverse events (>20%) were peripheral edema, nausea, vomiting, elevated blood creatinine, dyspnea, fatigue and loss of appetite
.

Lung cancer is the most common cancer in the world, with more than 2 million newly diagnosed cases each year
.

Currently, the 5-year survival rate for lung cancer is less than 20%
.

There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Among them, NSCLC accounts for about 80%-85% of all lung cancers
.

Nearly one-third of patients with metastatic NSCLC may have mutations, and the incidence of METex14 in metastatic NSCLC cases is 3%-4%
.

At present, clinical treatment options for clinical NSCLC patients are limited, and the prognosis is often poor
.

 "The launch of Tabrecta a year ago has greatly changed the treatment landscape for METex14 NSCLC patients
.

Now we have further evidence that it has the potential to extend patient life
.

" said Mr.
Jeff Legos, senior vice president of Novartis' oncology drug development department
.

Reference: [1] First Published Overall Survival and Updated Overall Response Data in Patients with METex14 metastatic NSCLC.
Retrieved June 4, 2021, from https:// -first-published-overall-survival-and-updated-overall-response-data-patients-metex14-metastatic-nsclc Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.

If you need guidance on the treatment plan, please go to a regular hospital for treatment
.